Information Provided By: 
Fly News Breaks for August 7, 2019
TXMD
Aug 7, 2019 | 09:17 EDT
Cantor Fitzgerald analyst Louise Chen reiterates an Overweight rating on TherapeuticsMD with a $13 price target following the company's "solid quarter of execution." TherapeuticsMD in premarket trading is up 10%, or 18c, to $2.05. Upward earnings revisions and multiple expansion to levels not reflected in consensus forecasts will drive the stock higher, Chen tells investors in a research note. The analyst anticipates better than expected uptake for Imvexxy, Bijuva and Annovera in 2019 and beyond.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
